Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Buprenorphine Added on Brief Cognitive Behavioral Therapy for Treatment of Methamphetamine Use Disorder Publisher



Shariatirad S1, 2 ; Mahjoub A1 ; Haqiqi A1 ; Hemami MR3 ; Tofighi B4 ; Ekhtiari H5, 6 ; Effatpanah M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Students Research Center of International Campus, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Substance Abuse and Dependence Research Center, University of SocialWelfare and Rehabilitation Sciences, Tehran, Iran
  3. 3. Institute of Health and Wellbeing, Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, United Kingdom
  4. 4. Department of Population Health, New York University School of Medicine, New York, United States
  5. 5. Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Iranian Institute for Cognitive Sciences Studies, Tehran, Iran

Source: Iranian Journal of Psychiatry and Behavioral Sciences Published:2018


Abstract

Background: Methamphetamine (MA) use remains a major public health concern around the world. Recent findings suggest that buprenorphine may be helpful for cocaine use reduction. Moreover, animal studies described reduced dopamine peak effect following MA use, due to the administration of low dose buprenorphine. Objectives: This study examined the effectiveness of buprenorphine with brief cognitive behavioral therapy on MA use disorder. Methods: The study was conducted in an outpatient substance abuse treatment center in Qazvin, Iran. Nineteen MA users received buprenorphine for 24 weeks combined with brief cognitive behavioral therapy in an outpatient substance abuse treatment program, three times per week, as a before and after non - randomization study. Clinical outcomes included treatment retention, MA use, degree of MA dependency and craving, quality of life, cognitive abilities questionnaire, addiction severity and also adverse events. Data was analyzed by performing repeated measures analysis and the Friedman test for nonparametric variables. Results: Fifteen participants completed the study during six months and frequency of MA use was significantly decreased at 24 weeks (P < 0.001). There were also significant reductions in craving (P < 0.001), degree of MA dependence (P < 0.001), and improvements in quality of life, cognitive ability, and some subscales of addiction severity. Conclusions: The results of this preliminary clinical study demonstrated that buprenorphine could potentially attenuateMAcraving and alternate rewarding effects of MAand had promising effects on cognitive impairment. Furthermore, buprenorphine can be considered as a harm reduction intervention in some communities, in which the people, as a result of cultural beliefs, do not accept a therapy, which only consists of counseling and no medications. ©2018, Iranian Journal of Psychiatry and Behavioral Sciences.
Other Related Docs